China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider, has reportedly raised over RMB 100 million (USD 14.3 million) in a Series B financing round. The round was led by Eight Roads and Sunland Fund, with contributions from Zhuhai Hi tech Financial Investment and Qiahe Capital. The proceeds will be directed towards product research and development, market promotion for self-owned brands, and expanding market share.
Company Background and Product Portfolio
Founded in 2010, Meihua Medtech has established itself as a prominent player in the diagnostic solutions space. The company offers more than 30 diagnostic instruments and supporting reagents across eight series, including MALDI-TOF mass spectrometry platform series products, microbial identification/drug sensitivity analyzers, and supporting reagent series products. This comprehensive portfolio positions Meihua Medtech to effectively address the needs of clinical microbiology laboratories.-Fineline Info & Tech
